BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
The vaccine was 85 percent effective in preventing severe disease across all regions.
Subscribe To Our Newsletter & Stay Updated
